FDA grants fast track designation to empagliflozin to treat chronic heart failure

This article was originally published here

The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedite the availability of new

The post FDA grants fast track designation to empagliflozin to treat chronic heart failure appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply